Agios Pharmaceuticals(AGIO) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Agios Reports Second Quarter 2025 Financial Results and Provides Business Update CAMBRIDGE, Mass., July 31, 2025 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial- stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and updates for the second quarter ended June 30, 2025. • $12.5 million in second quarter PYRUKYND® (mitapivat) net revenues; ended second quarter with $1.3 billion dollars in cash, ca ...